Codexis Appoints Biopharmaceuticals Industry Veteran, Patrick Yang, Ph.D., to Board of Directors

Codexis Appoints Biopharmaceuticals Industry Veteran, Patrick Yang, Ph.D., to
Board of Directors

REDWOOD CITY, Calif., Feb. 27, 2014 (GLOBE NEWSWIRE) -- Codexis, Inc.
(Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and
fine chemical industries, today announced the appointment of Patrick Yang,
Ph.D., to its board of directors. Dr. Yang brings significant experience in
pharmaceutical manufacturing and process development to the Codexis board,
following several executive leadership roles within the pharmaceutical
industry.

John Nicols, President and CEO of Codexis, said, "Dr. Yang's impressive track
record in the pharmaceuticals industry, including leadership positions at
Roche, Genentech and Merck, will bring valuable experience to our board. In
addition to leveraging his extensive network in the global pharmaceutical
industry, Codexis expects to greatly benefit from applying Dr. Yang's broad
operational and technological expertise to help accelerate the profitable
growth of our biocatalyst business going forward."

Dr. Yang commented, "I am excited to join the board of Codexis, particularly
at this important stage in the company's history. The pharmaceutical market is
the right focus for Codexis and its great technology, and now that Codexis is
fully focused on this market, I can use my 35 years of experience in this
industry to create value for both the company's shareholders and customers."

Dr. Yang served most recently as Executive Vice President and Global Head of
Technical Operations for F. Hoffmann-La Roche AG, a world leader in
research-focused pharmaceuticals and diagnostics. In this role, Dr. Yang was
responsible for Roche's pharmaceutical and biotech manufacturing operations,
process development, quality, regulatory, supply management and distribution
functions, and was accountable for more than 15,000 employees worldwide.

Previously, Dr. Yang worked for Genentech, a leading biotechnology company,
for about 10 years, where his most recent position was Executive Vice
President of Product Operations. At Genentech, Dr. Yang was responsible for
Genentech's manufacturing, process development, quality, regulatory affairs
and distribution functions. Prior to Genentech, Dr. Yang held several
leadership roles at Merck & Co., including Vice President of Asia/Pacific
Manufacturing Operations and Vice President of, Supply Chain Management. He
also previously worked at General Electric Co. and Life Systems, Inc. Dr. Yang
serves on the board of directors of Tesoro Corporation (NYSE:TSO), an
independent refiner and marketer of petroleum products.

Dr. Yang earned a Bachelor of Science in Engineering from the National
Chiaotung University in Taiwan, a Master of Science in Electrical Engineering
from the University of Cincinnati and a Ph.D. in engineering from the Ohio
State University.

AboutCodexis, Inc.

Codexis, Inc.is a leading developer of biocatalysts for pharmaceutical and
fine chemical production. Codexis' proven technology enables scale-up and
implementation of biocatalytic solutions to meet customer needs for rapid,
cost-effective and sustainable process development – from research to
manufacturing. For more information, seewww.codexis.com.

Forward-Looking Statements

This press release contains forward-looking statements relating to Codexis'
ability to accelerate the profitable growth of its biocatalyst business. You
should not place undue reliance on these forward-looking statements because
they involve known and unknown risks, uncertainties and other factors that
are, in some cases, beyond Codexis' control and that could materially affect
actual results. Factors that could materially affect actual results include
Codexis' need for additional capital in the future to expand its business;
Codexis' dependence on a limited number of products and customers in its
pharmaceutical business; Codexis' ability to develop and commercialize new
products for the pharmaceutical markets; Codexis' relationships with, and
dependence on, its collaborators in its principal markets; Codexis' ability to
deploy its technology platform in new market spaces; the success of Codexis'
customers' pharmaceutical products in the market and the ability of such
customers to obtain regulatory approvals for products and processes; and
Codexis' pharmaceutical product gross margins are variable and may decline
from quarter to quarter. Additional factors that could materially affect
actual results can be found in Codexis' Quarterly Report on Form 10-Q filed
with the Securities and Exchange Commission on November 12, 2013, including
under the caption "Risk Factors." Codexis expressly disclaims any intent or
obligation to update these forward-looking statements, except as required by
law.

CONTACT: Codexis, Inc.
         Investors
         Paul Cox, 212-362-1200
         ir@codexis.com
        
         Media
         Kate Whelan, +46 72 216 98 49
         kate.whelan@notchcommunications.co.uk

Codexis logo
 
Press spacebar to pause and continue. Press esc to stop.